BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...Phase III COVE study of mRNA-1273, a COVID-19 vaccine co-developed by Moderna and NIH.Morningside Ventures’ Immetas debuts Immetas Therapeutics...
Items per page:
1 - 1 of 1
BioCentury | Sep 25, 2020
Finance

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

...Phase III COVE study of mRNA-1273, a COVID-19 vaccine co-developed by Moderna and NIH.Morningside Ventures’ Immetas debuts Immetas Therapeutics...
Items per page:
1 - 1 of 1